Qlife advances pharmaceutical collaboration into partner-financed product-readiness phase aimed at a clinical development and commercialisation partnership

The new phase follows the successful completion of the initial feasibility work announced in September 2026 and represents the next step towards a clinical development and commercialisation partnership.

The pharmaceutical partner will finance the product-readiness phase with approximately SEK 2.7 million. Together with SEK 1.5 million already financed for the initial phase, total partner funding of the collaboration amounts to approximately SEK 4.2 million.

The work completed to date has substantially narrowed the remaining technical scope. The Egoo platform and the assay are considered sufficiently verified for the current stage. This allows the product-readiness phase to concentrate on the remaining sample preparation step and its integration into the complete testing workflow.

Targeting decentralized pharmaceutical treatment monitoring

The pharmaceutical partner develops and commercializes specialized therapies for serious chronic conditions where treatment can require close and repeated biochemical monitoring. The collaboration is focused on adapting the Egoo platform for measurement of a clinically important biomarker used in pharmaceutical treatment monitoring.

Structured as a bridge into formal development

The product-readiness program is planned as a focused 12-week technical phase followed by a four-week mobilization period. Subject to successful completion of the product-readiness work and a subsequent agreement between the parties, the intended next step is a full-scale program covering formal product and regulatory development until market clearance.

Comment from Thomas Warthoe, CEO of Qlife

“We see this as an important progression in the collaboration. We have structured the product-readiness phase so that successful work can carry directly into a clinical development and commercialisation partnership. For Qlife, this is exactly how we want pharmaceutical collaborations to develop: from initial technical evaluation, through focused product readiness, into clinical programs followed by licensing and commercialisation. While progression remains subject to the successful outcome of this phase and a subsequent agreement between the parties, we believe the partner’s continued financial commitment is an important endorsement of the progress achieved and the potential of the collaboration.”

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2026-11-11 17:30 CET.